Quick Answer
Galmed Pharmaceuticals Ltd. reported R&D Expense of $4.87 million for fiscal year 2025.
Galmed Pharmaceuticals Ltd. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $4.87M | +63.6% |
| 2024 | $2.98M | -16.5% |
| 2023 | $3.57M | -72.5% |
| 2022 | $12.99M | -52.3% |
| 2021 | $27.22M | +4.4% |
| 2020 | $26.08M | +43.5% |
| 2019 | $18.18M | +118.7% |
| 2018 | $8.31M | -13.9% |
| 2017 | $9.65M | -32.4% |
| 2016 | $14.27M | +87.1% |
| 2015 | $7.63M | +14.5% |
| 2014 | $6.66M | -7.5% |
| 2013 | $7.21M | +195.0% |
| 2012 | $2.44M | — |
- Galmed Pharmaceuticals Ltd. showed an increase of +63.6% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, Galmed Pharmaceuticals Ltd.’s r&d expense has grown by 99.5% (from $2.44 million to $4.87 million).
- The most recent figure is from Galmed Pharmaceuticals Ltd.’s fiscal year 2025 report (Form 20-F), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: